Clinical Trials Browser

Carcinoid Tumor, Vipoma, Pancreatic Neoplasms, Pheochromocytoma, Somatostatinoma, Zollinger-Ellison Syndrome, Gastrinoma, Carcinoma, Medullary, Neuroendocrine Tumors

NCT00416767 2016-05-30

Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery

Phase 2 Completed

20 enrolled

Endocrine

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

NCT00227773 2015-10-08

Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors

Phase 2 Withdrawn

Endocrine

Vipoma, Glucagonoma, Insulinoma, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

NCT00602082 2013-08-07

Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors

Phase 2 Completed

84 enrolled

Endocrine

Glucagonoma, Insulinoma, Adenoma, Islet Cell, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

NCT00027638 2013-06-18

Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors

Phase 2 Completed

EndocrineThoracic

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Lung Neoplasms, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

NCT00075439 2013-06-04

Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors

Phase 2 Completed

90 enrolled

Endocrine

Vipoma, Glucagonoma, Insulinoma, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

NCT00084461 2013-06-04

Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors

Phase 2 Terminated

25 enrolled

Endocrine

Glucagonoma, Insulinoma, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

NCT00017199 2013-01-31

PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors

Phase 2 Completed

Endocrine

Glucagonoma, Insulinoma, Adenoma, Islet Cell, Somatostatinoma, Gastrinoma

NCT00466856 2012-05-18

Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors

Phase 2 Terminated

10 enrolled

EndocrineHead & Neck

Vipoma, Glucagonoma, Head and Neck Neoplasms, Insulinoma, Adenoma, Islet Cell, Neoplasm Metastasis, Neoplasms, Pheochromocytoma, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Carcinoma, Medullary

Clinical Trials

AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors

Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery

177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs

EPO906 in Carcinoid and Other Neuroendocrine Tumors

Capecitabine and Temozolomide for Neuroendocrine Cancers

Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery

Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors

Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors

Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors

Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors

Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors

PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors

Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors